(2026). Cutaneous Rosai‐Dorfman Disease With MAP2K1 Mutation Treated With Encorafenib and Binimetinib. JEADV Clinical Practice.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Cutaneous Rosai‐Dorfman Disease With MAP2K1 Mutation Treated With Encorafenib and Binimetinib."
JEADV Clinical Practice 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Cutaneous Rosai‐Dorfman Disease With MAP2K1 Mutation Treated With Encorafenib and Binimetinib."
JEADV Clinical Practice, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.